<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082835</url>
  </required_header>
  <id_info>
    <org_study_id>0081122</org_study_id>
    <nct_id>NCT01082835</nct_id>
  </id_info>
  <brief_title>Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat)Clinical Study</brief_title>
  <acronym>JZQG</acronym>
  <official_title>Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat), Randomized, Parallel-controlled, Multi-center Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Jangzhuo Qinggan prescription and irbesartan in the treatment of essential&#xD;
      hypertension(Hepatogastric Damp-heat), randomized, parallel-controlled, multi-center clinical&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Charged by the five research centers in line with traditional Chinese medicine hepatogastric&#xD;
      Damp-heat syndrome 240 cases have hypertension, and overweight, as well as blood lipid&#xD;
      disorders or diabetes were randomly divided into Chinese herbal compound Jiangzhuo Qinggan&#xD;
      prescription group and western medicine irbesartan group.The treatment groups were compared&#xD;
      4-week step-down and regulation of blood lipids, blood sugar effect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Hypertension</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>the group of Jiangzhuo Qinggan prescription</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>the group of irbesartan</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Combined metabolic syndrome in patients with essential hypertension&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Consistent with diagnosed hypertension, blood pressure, for 1-2 grade.&#xD;
&#xD;
          2. Aged 18-65 years old.&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 24kg/m2, but &lt;35 kg/m2.&#xD;
&#xD;
          4. Waist circumference ≥ 85cm (male) or waist circumference ≥ 80cm (women).&#xD;
&#xD;
          5. Comply with any of the following 3 : triglyceride (TG) elevated levels of:&gt; 150mg/dl&#xD;
             (1.7mmol / l), or has received appropriate treatment; high-density lipoprotein -&#xD;
             cholesterol (HDL-C) levels reduced: Men &lt;40mg/dl (0.9mmol / l), women &lt;50mg/dl&#xD;
             (1.1mmol / l), or has received appropriate treatment; fasting plasma glucose (FPG)&#xD;
             increased: FPG ≥ 100mg/dl (5.6mmol / l ), or previously diagnosed type 2 diabetes or&#xD;
             have received appropriate treatment.&#xD;
&#xD;
          6. Hepatogastric Damp-heat syndrome differentiation.&#xD;
&#xD;
          7. To sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has been used to control lipids, blood sugar drugs, but use the time for those below&#xD;
             the 1 month.&#xD;
&#xD;
          2. Nearly 3 months, weight loss ≥ 5%.&#xD;
&#xD;
          3. Suffering from congenital heart disease, rheumatic heart disease, congestive heart&#xD;
             failure, unstable angina, and had a myocardial infarction, percutaneous transluminal&#xD;
             coronary angioplasty (PTCA) or off-line clinical significance of arrhythmia.&#xD;
&#xD;
          4. Bilateral renal artery stenosis, solitary kidney, serum creatinine&gt; 133μmol / L .&#xD;
&#xD;
          5. Active liver disease, history of chronic persistent hepatitis, ALT&gt; upper limit of&#xD;
             normal.&#xD;
&#xD;
          6. Peptic ulcer or malabsorption syndrome .&#xD;
&#xD;
          7. With insulin-treated diabetes.&#xD;
&#xD;
          8. There is a history of appetite or abuse of laxatives by hyperthyroidism.&#xD;
&#xD;
          9. Pregnancy, pregnancy or breast-feeding women to prepare.&#xD;
&#xD;
         10. For those who are allergic Chinese medicine, allergic people.&#xD;
&#xD;
         11. Mentally ill.&#xD;
&#xD;
         12. Hyperkalemia in patients.&#xD;
&#xD;
         13. Cancer.&#xD;
&#xD;
         14. Occurred within the past 6 months who had a stroke or transient ischemic attack (TIA).&#xD;
&#xD;
         15. Nearly 3 months in patients receiving other clinical studies.&#xD;
&#xD;
         16. Alcohol and / or psychoactive substances, drug abuse and dependency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fenglian Li, PHD</last_name>
    <phone>0086-010-88001402</phone>
    <email>lfm565@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Medical University ,Dongzhimen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weixing Lu</last_name>
      <phone>0086-013601067938</phone>
      <email>weixinglu918@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Medical University,Dongfang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qian Lin</last_name>
      <phone>0086-013910565673</phone>
      <email>dfluyao@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Academy of Chinese Medical Sciences,Guang'anmen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qiang Zhou</last_name>
      <phone>0086-015101016416</phone>
      <email>tiantianlanzhouqiang@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences Fu Wai Cardiovascular Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianfeng Huang</last_name>
      <phone>0086-010-88396403</phone>
      <email>jianfhuang918@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capital University of Medical, Anzhen Hospital</name>
      <address>
        <city>Beijng</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhenqiu Yu</last_name>
      <phone>0086-010-64456577</phone>
      <email>yuzhenqiu@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <last_update_submitted>March 15, 2010</last_update_submitted>
  <last_update_submitted_qc>March 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Guang'anmen Hospital</name_title>
    <organization>China Academy of Chinese Medical Sciences</organization>
  </responsible_party>
  <keyword>Chinese herbs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

